Sali e Derivati degli API

<p>Applications Allopurinol is a xanthine oxidase inhibitor; decreases uric acid production. Used in treatment of hyperuricemia and chronic gout. Antiurolithic.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Benezra, S.A., et al.: Anal. Profiles Drug Subs., 7, 1, (1978); Dalbeth, N., et al.: Rheumatology, 44, 1090 (2005); Dinarello, C., et al.: J. Exp. Med., 201, 1355 (2005);<br></p>

<p>Applications A metabolite of Levosimendan.<br>References Rubinstein, A., et al.: J. Pharmacol. Met., 19, 213 , (1988), Pollesello, P., et al.: J. Biol. Chem., 269, 28584 (1994), Yokoshiki, H., et al.: Eur. J. Pharmacol., 333, 249 (1997)<br></p>

<p>Applications Apixaban PG Ester-II is one of the multiple constituents extracted from Biebersteinia multifida, that exhibits inhibitory activity on acetylcholinesterase.<br>References Xiang, F., et al.: Faming Zhuanli Shenqing (2019), CN 109432093 A 20190308.<br></p>

<p>Applications A potent, direct, selective, and orally active inhibitor of coagulation factor Xa. It is a potential new oral coagulant that may be useful prevention of venous thromboembolism in total hip, knee replacement orthopedic surgery and stroke in treatment of patient with venous thromboembolic disorder or with atrial fibrillation.<br>References Luettgen, J. M., et al.: J. Enz. Inhib. Med. Chem., 26, 514 (2011); Glanis, T., et al.: J. Thromb. Thrombol., 31, 310 (2011); Barrett, Y. C., et al.: Thromb. Haemos., 105, 181 (2011);<br></p>

<p>Applications R-(+)-Warfarin-d5 is the isotope labelled analog of R-(+)-Warfarin, an enantiomer of Warfarin (W498500). Coumarin anticoagulant.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Hagan, E.C., et al.: J. Am. Pharm. Assoc. Sci. Ed., 42, 379 (1953), Bell, R.G., et al.: Biochemistry, 11, 1959 (1972), Valente, J.E., et al.: J. Med. Chem., 20, 1489 (1977), Back, N., et al.: Pharmacol. Res. Commun., 10, 445, (1978), Babhair, S.A., et al.: Anal. Profiles Drug Subs., 14, 423 (1985), Takahashi, H., et al.: Echizen, Clin. Pharmacokinet., 40, 587 (2001),<br></p>

<p>Stability Hygroscopic<br>Applications The major metabolite of Probenecid (P755000).<br>References Blanckaert, N., et al.: Biochem. J., 171, 203 (1978), Worrall, S., et al.: Life Sci., 56, 1921 (1995), Presle, N., et al.: Drug Metab. Disos., 24, 1050 (1996), Akira, K., et al.: J. Pharmacol. Toxicol. Methods, 37, 237 (1997), Terrier, N., et al.: Mol. Pharmacol., 56, 226 (1999),<br></p>

<p>Applications 3'-Hydroxy-4'-methoxydiclofenac is a derivative of Diclofenac (Sodium Salt: D436450). Diclofenac is the first non-steroidal anti-inflammatory drug (NSAID) that is derived from phenylacetic acid. Diclofenac, like other NSAIDs, primarily works by targeting the cyclo-oxygenase pathway in the arachidonic acid cascade, reducing the formation of inflammation mediators in the body.<br>References Ku, E., et al.: Am. J. Med., 80, 18 (1986); Simmons, D., et al.: Proc. Nat. Acad. Sci., 96, 3275 (1999); Small, R.: Clin. Pharm., 8, 545 (1989)<br></p>

<p>Applications Selexipag is an orally available, highly selective, long-acting prostacyclin (IP) receptor agonist prodrug. It is a potential drug for the treatment of various vascular disorders such as pulmonary arterial hypertension and arteriosclerosis obliterans.<br>References Kuwano, K., et al.: J. Pharm. Exp. Ther., 322, 1181 (2007);<br></p>

<p>Applications Labelled Bosentan (B675900). A mixed endothelin receptor antagonist. Used as a vasodilator. Antihypertensive.<br>References Clozel, M., et al.: J. Pharmacol. Exp. Ther., 270, 228 (1994), Gutsch, G., et al.: Cardiovasc. Drugs Ther., 10, 717 (1996), Weber, C., et al.: Clin Pharmacol. Ther., 60, 124 (1996), Krum, H., et al.: N. Engl. J. Med., 338, 784 (1998)<br></p>

<p>Applications Labelled Tolvaptan. It is a selective, competitive arginine vasopressin V2 receptor antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH).<br>References Paterna, S., et al.: Eur. J. Heart Fail, 2, 305 (2000), Udelson, J., et al.: Circulation, 104, 2417 (2001), Goldsmith, S., et al.: J. Am. Coll Cardiol., 46, 1785 (2005), Schrier, R., et al.: N. Engl. J. Med., 355, 2099 (2006),<br></p>

<p>Applications Labelled Zephirol. Quaternary ammonium composition to treat herpes, pseudomonas, staph, hepatitis and other infectious diseases.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Berr, S., et al.: J. Phys. Chem., 91, 4760 (1987), Jones, M., et al.: Eur. J. Pharm. Biopharm., 48, 101 (1999), Okano, L., et al.: Langmuir, 16, 3119 (2000),<br></p>

<p>Applications A metabolite of Repaglinide (R144500).<br>References Jarvis, B., et al.: Drugs, 59, 891 (2000), Niemi, M., et al.: Clin. Pharmacol. Ther., 70, 58 (2001), Hatorp, V., et al.: Clin. Pharmacokinet., 41, 471 (2002), Walsky, R., et al.: Drug Metab. Dispos., 33, 413 (2005),<br></p>

<p>Impurity Ramipril EP Impurity N<br>Applications (2R,3aR,6aR)-Ramipril (Ramipril EP Impurity N) is an isomer of the angiotensin-converting enzyme (ACE) inhibitor Ramipril (R111000). Ramipril impurity N.<br>References Hogan, B.L. et al.: J. Pharmac. Biomed. Anal., 23, 637 (2000); Ito, M. et al.: J. Liq. Chrom., 13, 991 (1990);<br></p>

<p>Applications 1,2,3,4-Tetrahydro Argatroban is a metabolite of Argatroban (A769000); a synthetic thrombin inhibitor and antithrombotic.<br>References Abiko, Y., et al.: Thromb. Res., 24, 285 (1981); Kikumoto, R., et al.: Biochemistry, 23, 85 (1984)<br></p>

<p>Applications Macitentan-d4 is an isotopic form of Macitentan (M105005). Macitentan, is an orally active endothelin receptor antagonist used for pulmonary arterial hypertension.<br>References Emoto, N. Ensho to Men'eki, 20, 487 (2012);<br></p>

<p>Applications Apixaban PG Ester-I is one of the multiple constituents extracted from Biebersteinia multifida, that exhibits inhibitory activity on acetylcholinesterase.<br>References Xiang, F., et al.: Faming Zhuanli Shenqing (2019), CN 109432093 A 20190308.<br></p>

<p>Applications Latanoprost Acid-d4 is the labeled analogue of Latanoprost Acid (L177310), a metabolite of Latanoprost. Latanoprost Acid (L177310) is a potent, selective FP prostanoid receptor agonist, a F-series Prostaglandin analog and is 200 times as potent as isopropyl ester form.<br>References Sjoquist, B., et al.: Drug Metab. Dispos., 26, 745 (1998), Watson, P., et al.: Drugs Today, 35, 449 (1999), Kashiwagi, K., et al.: Exp. Eye Res., 74, 41 (2002),<br></p>

<p>Applications Diagnostic aid (radiopaque medium).<br>References Gallotti, A., et al.: Eur. J. Radiol., 18, Suppl 1 S1(1994), Morisetti, A., et al.: Eur. J. Radiol., 18, Suppl 1 S21(1994).<br></p>

<p>Stability Light Sensitive<br>Applications Bimatoprost is an antiglaucoma agent. Bimatoprost is an synthetic prostamide; structurally related to prostaglandin F2α.<br>References Brandt, J.D., et al.: Ophthalmology, 108, 1023 (2001), Woodward, D.F., et al.: J. Pharmacol. Exp. Ther., 305, 772 (2003), Quinones, R., et al.: J. Ocul. Pharmacol. Ther., 20, 115 (2004),<br></p>

<p>Applications Boc-L-Nitroarginine, can be used in peptide chemistry. It has been also shown to act as NO synthase inhibitor, and thus used in the study of The effects of methylene blue (MB) for treatment of sepsis induced by bowel perforation.<br>References Galili, Y. Euro. surg. Rese. vol. 29, P:390-395 (19997);<br></p>

<p>Stability Hygroscopic<br>Applications A drug used for the treatment of atrial fibrillation and atrial flutter in patients who have suffered cardiac arrhythmias.<br>References Singh, B., et al.: J. Cardiovas. Pharmacol., 52, 300 (2008), Hoy, S., et al.: Drugs, 69, 1647 (2009), Hohnloser, S., et al.: New Eng. J. Med., 360, 668 (2009),<br></p>

<p>Applications A labelled antihypertensive. An angiotensin converting enzyme (ACE) inhibitor, converted to active, diacid metabolite.<br>References Teetz, V., et al.: Arzneim.-Forsch., 34, 1399 (1984), Ruggenenti, P., et al.: Lancet, 352, (1998), Bosch, J., et al.: Br. Med. J., 324, 1 (2002),<br></p>

<p>Applications 4-(3-Aminophenyl)-3-morpholinone is an intermediate during the preparation of imidazothiazoles as protein kinase inhibitors for treating cancers.<br>References Bamaung, N., et al.: PCT Int. Appl. (2009), WO 2009070516 A1 20090604.<br></p>

<p>Applications Edaravone D5 is the labelled compound of Edaravone(E335000). synthesized and used for relative quant. anal. of oligosaccharides by mass spectrometry (MS). Edaravone inhibits the disease activity in rheumatoid arthritis. Edaravone can significantly enhance IR flap viability and protect flap vessels, which is related to scavenging oxygen free radicals, reducing the consumption of SOD, reducing the extent of lipid peroxidation and inflammation, and protecting functional structure of vessels in the early stages of reperfusion. It also shows protective effects against STZ-induced cognitive impairment, oxidative stress, cholinergic dysfunction and altered protein expressions. Its acts like a free radical scavenger, decreased apoptotic cell death, oxidative damage to DNA and lipids, and angiogene<br>References Zhang, Ping, et al.: Anal. Biochem., 418, 1(2011)<br></p>

<p>Applications A labelled metabolite of Ramipril (R111000).<br>References Teetz, V., et al.: Arzneim.-Forsch., 34, 1399 (1984), Ruggenenti, P., et al.: Lancet, 352, (1998), Bosch, J., et al.: Br. Med. J., 324, 1 (2002),<br></p>

<p>Applications A metabolite of Rivaroxaban (R538000).<br>References Kubitza, D., et al.: Clin. Pharmacol. Ther., 78, 412 (2005), Roehrig, S., et al.: J. Med. Chem., 48, 5900 (2005), Biemond, B., et al.: Thromb. Haemost., 97, 471 (2007), Lang, D., et al.: Drug Metab. Dispos., 37, 1046 (2009),<br></p>

<p>Applications An antihypertensive. Angiotensin converting enzyme (ACE) inhibitor.<br>References Brown, N.L., et al.: Eur. J. Pharmacol., 148, 79 (1988), Kober, L., et al.: N. Engl. J. Med., 333, 1670 (1995), Malik, R.A., et al.: Lancet, 352, 1978 (1998)<br></p>

<p>Applications An immunosuppressive. Inhibits T and B cell proliferation. Activity is attributed mainly to its metabolite, a malononitrile derivative, which is beleived to inhibit dihydroorotate dehydrogenase as well as several protein tyrosine kinases.This compound is suitable for dihydroorotate dehydrogenase (DHODH) related research.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Vrenken, T., et al.: J. Hepatol., 49, 799 (2008), Mazzucco, G., et al.: Clin. Nephrol., 70, 163 (2008), Davies, M., et al.: J. Med. Chem., 52, 2683 (2009),<br></p>

<p>Applications Riociguat-13C-d3 is the labelled analogue of Riociguat (R520000), which is used in the treatment for pulmonary hypertension.<br>References Frey, R. et al.: J. Clin. Pharmacol., 51, 1051 (2011);<br></p>

<p>Applications Nonionic, injectable radio-contrast medium. Diagnostic aid (radiopaque medium).<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Muetzel, W., et al.: Am.J. Neuroradiol., 4, 350 (1983), Dawson, P., et al.: Acta Radiol. Diagn., 25, 253 (1984),<br></p>

<p>Applications Sodium Chlorite is used as a bleaching agent for cotton textiles.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Shenai, V.A., Pai, S.M.: Textile Dyer Printer, 3, 153 (1969)<br></p>

<p>Applications (15R)-Bimatoprost Acid is an impurity of the antiglaucoma agent Bimatoprost (B386820). (15R)-Bimatoprost Acid is a metabolically stable analog of PGF2α (P838625) and is a potent agonist for the FP receptor.<br>References Balapure, A.K. et al.: Biochem. Pharmacol., 38, 2375 (1989); Hellberg, M.R. et al.: J. Ocular Pharmacol. Ther., 19, 97 (2003); Krishna, P.M. et al.: J. Pharm. res., 4, 2381 (2011); Resul, B., et al.: J. Med. Chem., 36, 243 (1993)<br></p>

<p>Applications Tacrolimus Hydrate is a disease-modifying antirheumatic drugs (DMARDs)<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Ogasawara, M., et al.: Mod. Rheumatol., 22, 831-836 (2012)<br></p>

<p>Applications A novel antithrombotic agent. A highly potent and selective, direct FXa inhibitor.<br>References Ansell, J., et al.: Drugs, 64, 1 (2004), Eriksson, B., et al.: J. Thromb. Haemost., 3, 103 (2005), Kubitza, D., et al.: Clin. Pharmacol. Ther., 78, 412 (2005),<br></p>

<p>Applications An immunosuppressive. Inhibits T and B cell proliferation. Activity is attributed mainly to its metabolite, a malononitrile derivative, which is beleived to inhibit dihydroorotate dehydrogenase as well as several protein tyrosine kinases. Therapeutically as a antirheumatic (Merck Index).This compound is suitable for dihydroorotate dehydrogenase (DHODH) related research.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Vrenken, T., et al.: J. Hepatol., 49, 799 (2008), Mazzucco, G., et al.: Clin. Nephrol., 70, 163 (2008), Davies, M., et al.: J. Med. Chem., 52, 2683 (2009),<br></p>

<p>Impurity Leflunomide USP Related Compound B<br>Applications rac A77 1726 is the active metabolite of Leflunomide, a potent disease-modifying antirheumatic drug used in the treatment of rheumatoid arthritis. LEF-M interferes with dendritic cell function. The second Phase III study evaluating the efficacy of Genzyme’s teriflunomide therapy against relapsing forms of multiple sclerosis found the once-daily oral drug to be no less effective than injectable interferon beta 1a (Rebif®). Leflunomide USP Related Compound B.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Kirsch, B.M., et al.: Arthritis Research and Therapy, 7, 3, R694, (2005)<br></p>

<p>Applications 4-(2-Aminophenyl)-3-morpholinone is a reagent used in the preparation of various Morpholine based pharmaceuticals.<br>References Mederski, W., et al.: Bioorg. Med. Chem. Lett., 14, 3763 (2004), Roehrig, S., et al.: J. Med. Chem., 48, 5900 (2005),<br></p>

<p>Applications Apixaban-d3 is labelled Apixaban (A726700) which is a potent, direct, selective, and orally active inhibitor of coagulation factor Xa. It is a potential new oral coagulant that may be useful prevention of venous thromboembolism in total hip, knee replacement orthopedic surgery and stroke in treatment of patient with venous thromboembolic disorder or with atrial fibrillation.<br>References Luettgen, J.M. et al.: J. Enz. Inhib. Med. Chem., 26, 514 (2011); Glanis, T. et al.: J. Thromb. Thrombol., 31, 310 (2011); barrett, Y.C. et al.: Thromb. Haemos., 105, 181 (2011);<br></p>

<p>Applications An antihypertensive. An angiotensin converting enzyme (ACE) inhibitor, converted to active, diacid metabolite. Neuroprotective &amp; Neuroresearch Product.<br>References Teetz, V., et al.: Arzneim.-Forsch., 34, 1399 (1984), Ruggenenti, P., et al.: Lancet, 352, (1998), Bosch, J., et al.: Br. Med. J., 324, 1 (2002),<br></p>

<p>Applications The essential intermediate metabolite from which the active metabolite of Clopidogel is formed.<br>References Feliste, R., et al.: Thromb. Res., 48, 403 (1987), Savi, P., et al.: Biochem. Pharmacol., 44, 527 (1992), Herbert, J., et al.: Cardiovasc Drug. Rev., 11, 180 (1993), Sugidachi, A., et al.: B. J. Pharmacol., 132, 47 (2001)<br></p>